Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMXVRI0)

Drug Name
Beclanorsen Drug Info
Synonyms SPC-2004; SPC-2993; SPC-2996; Anti-Bcl-2 (LNA antisense therapy), Santaris
Indication
Disease Entry ICD 11 Status REF
leukaemia 2A60-2B33 Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DMXVRI0

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
BCL-2 messenger RNA (BCL2 mRNA) TTFOUV4 BCL2_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
BCL-2 messenger RNA (BCL2 mRNA) DTT BCL2 3.963 4.739 4.146 4.878
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease leukaemia
ICD Disease Classification 2A60-2B33
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
BCL-2 messenger RNA (BCL2 mRNA) DTT BCL2 8.27E-03 0.06 0.13
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT00285103) SPC2996 in Chronic Lymphocytic Leukaemia. U.S. National Institutes of Health.
2 Combination of novel imidazopyridazine mps-1 kinase inhibitors and bcl-2 family protein inhibitors. ACS Med Chem Lett. 2014 Jul 30;6(1):7-8.